commercialization

WuXi AppTec has recently come under fire from U.S. politicians who want to ban government-backed projects from buying its services, causing the stock to lose about half of its value this year.

FAST NEWS: BlackRock boosts stake in battered WuXi AppTec

The latest: Asset management company BlackRock Inc. purchased 618,000 Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) on March 26, raising its stake in the drug outsourcing services company from…
2359.HK 603259.SHG
Biotech company Zai Lab reported Wednesday that its loss narrowed 24.5% to $335 million last year.

FAST NEWS: Zai Lab’s loss narrows on strengthening sales

The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) reported Wednesday that its loss narrowed 24.5% to $335 million last year. Looking up: The narrower loss owed mainly to a 25% increase in revenue…
9688.HK ZLAB.US
U.S. banking giant JPMorgan purchased 1.57 million Hong Kong-listed shares of WuXi AppTec for HK$75.33 million on Feb. 8.

FAST NEWS: JPMorgan boosts WuXi AppTec stake

The latest: U.S. banking giant JPMorgan purchased 1.57 million Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) for HK$75.33 million ($9.66 million) on Feb. 8, raising its stake in the drug…
2359.HK 603259.SHG
Biotech company Zai Lab announced Wednesday that its loss narrowed 57% to $69.15 million in the third quarter from $161 million a year earlier.

FAST NEWS: Zai Lab’s loss narrows on growing revenue

The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) announced Wednesday that its loss narrowed 57% to $69.15 million in the third quarter from $161 million a year earlier. Looking up: The…
ZLAB.US 9688.HK
CStone Pharmaceuticals on Tuesday announced that its CEO Jason Yang plans to buy up to HK$5 million worth of the company’s shares in the open market over the next six months.

FAST NEWS: CStone says CEO to boost company holdings

The latest: CStone Pharmaceuticals (2616.HK) on Tuesday announced that its CEO Jason Yang plans to buy up to HK$5 million ($640,000) worth of the company’s shares in the open market over the…
2616.HK

Recent Articles

RELATED ARTICLES

  1. Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.
    Akeso marks profit milestone with swift rights issue
    9926.HK
  2. Drug maker Junshi seeks Swiss cure for cash woes
    1877.HK 688150.SHG
  3. BeiGene goes for global growth with sales and R&D push
    BGNE.US 6160.HK
  4. BeiGene still bleeding red ink despite blockbuster drug
    BGNE.US 6160.HK 688235.SHG
  5. Sales success comes with side effects for drug maker BeiGene
    BGNE.US 6160.HK
  6. Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
    1877.HK 688180.SHG
  7. Everest reaches new heights on growing drug sales
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners